Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Intravenous theophylline is the most effective intervention to prolong EEG seizure duration in patients undergoing electroconvulsive therapy

BMC AnesthesiologyBMC series – open, inclusive and trusted201717:114

https://doi.org/10.1186/s12871-017-0412-5

Received: 8 February 2017

Accepted: 25 August 2017

Published: 29 August 2017

Abstract

Background

Seizure duration in electroconvulsive therapy (ECT) is positively related with patients’ outcome. This study sought to investigate the impact of anesthetic management on seizure duration, and the impact of selected drugs (theophylline, remifentanil, S-ketamine) on seizure duration.

Methods

Retrospective analysis of all patients undergoing ECT at our institution from January 2011 to April 2012 was performed based on electronic medical chart and review of existing quality improvement data. Patient data (N = 78), including gender, age, height, weight, and administered drugs, energy levels, and electroencephalic seizure duration were analyzed. Statistical analysis was performed using a generalized linear model.

Results

A total of 78 patients (male = 39, female = 39, age 51 ± 12 years) were included. Average number of session was 10 ± 6 (1–30). In our patient population, theophylline administration was the only parameter, which significantly prolonged seizure duration, whereas S-ketamine, remifentanil, thiopental, age, sex, session or energy level had no significant effect.

Conclusion

Theophylline can be a useful adjunct for patients with inadequate seizure duration. If there is a concomitant beneficial effect on patients’ outcome needs to be investigated in further studies.

Keywords

ECT Seizure duration Theophylline Remifentanil (S-)ketamine Barbiturate Thiopental Etomidate Abbreviations. ECT Electroconvulsive therapy EEG Electroencephalogram. US United States.

Background

Since the introduction of convulsive therapy by Ladislav Meduna in 1934 [1] and the first treatment in Germany performed at our institution in 1937 [2], major modifications have been made to this treatment in order to improve outcome and patients’ acceptance. Today electroconvulsive therapy (ECT) is one of the most effective treatments for patients with major depression and persistent psychosis [3] and is performed under general anesthesia with muscle relaxation. Since suicide is a leading cause of death among psychiatric patients, and also a leading cause of death from all causes in people younger than 30 years [4], many investigations to improve efficacy of ECT have been made in the last years [5].

Several studies thereby focused on drug management, for example S-ketamine was shown to lead to longer motor seizure duration than metohexital [6]. When etomidate was given for induction of anesthesia longer motor and electroencephalographic (EEG) seizures were observed compared to propofol [7]. Propofol dose dependently reduces seizure duration [8]. Aminophyllines like theophylline increase seizure duration [3].

Only a few studies focused on other parameters potentially affecting seizure quality for example demographic factors like age or gender, interventions to lower seizure threshold, or modifications to seizure induction such as stimulus duration or energy level. Older patients were shown to have relatively short (clonic phase) seizure duration [9], and an inverse relationship between ECT intensity and the clonic phase of induced seizure [9] was found.

Despite these investigations no standard therapy is currently considered to be the gold standard. Therefore authors routinely use a step up approach, which starts with barbiturates followed by etomidate, if the seizure duration with barbiturate induction is inadequate. If seizure duration is still too short with etomidate induction, other adjuncts, such as remifentanil, theophylline, S-ketamine, or a combination of these drugs is being used or the stimulation intensity is increased. The goal of this retrospective study was to investigate in a relatively large patient population which single action significantly prolonged seizure duration in patients undergoing ECT.

Methods

Study design

We retrospectively reviewed the medical charts of 78 patients who underwent a total of 786 ECT sessions. The patients were identified from the anesthesia electronical medical chart database (NarkoData, Hüttenberg, Germany). Other data (energy levels, EEG seizure duration) were derived from a quality improvement database at the psychiatry department. All patients were diagnosed with severe depression, which did not respond to pharmacological therapy. A psychiatrist made the decision for ECT. Patient data (including age, height, weight, and gender), administered drugs, energy levels, and seizure duration as measured by EEG were analyzed. We excluded patients with the need of bitemporal stimulation, patients who had to undergo a second therapy interval and patients that were taking medications that might alter seizure threshold such as benzodiazepines or bupropion.

The study was approved by the ethics committee of the University Erlangen-Nuremberg by short correspondence from May 2012 without the need of informed consent.

Anesthesia

Anesthesia was performed as described previously [10]. In all patients standard monitoring, i.e. electrocardiography, automatic blood pressure measurement, pulse oximetry, and an intravenous catheter were established. Patients were preoxygenated with 100% oxygen by face mask for 3 min and either 5 mg/kg thiopental or 0.15 to 0.2 mg/kg etomidate was injected for induction of anesthesia. If necessary – see explanation below – application of remifentanil bolus of 0.5 μg/kg, 2 mg/kg theophylline or 0.3 mg/kg S-ketamine was added. After loss of consciousness 0.9 to 1.2 mg/kg succinylcholine was administered. Bag mask ventilation with 100% oxygen was performed by hyperventilating patients to achieve an end-tidal carbon dioxide of 27 to 30 mmHg. After relaxation a bite block was inserted and the electrical stimulus was applied in apnea by the psychiatrist. Energy level was chosen based upon the previous session by the anesthesiologist and psychiatrist. In the first treatment session energy level was set by titrating the individual seizure threshold.

After EEG seizure termination a bolus of 0.5 mg/kg propofol was injected to minimize risk of postictal agitation. Manually ventilation was again initiated until sufficient spontaneous breathing, i.e. patent airway without naso- or oropharyngeal airway and tidal volumes greater than 5 mL/kg body weight. Afterwards patients were transferred to the post anesthesia care unit where monitoring was continued until patients were brought back to the ward.

After each session the anesthesiologist and the psychiatrist decided depending on observed EEG seizure duration if there was a need to switch the induction agent from thiopental to etomidate or for the application of one or more additional drug(s), i. e. remifentanil, theophylline, or S-ketamine, or an increase of energy level for the next ECT session for the individual patient. Thereby only one parameter was changed or added for the next session.

Electroconvulsive therapy

ECT was performed standardized in a series of single ECT sessions (2 or 3 times a week) under general anesthesia as described above. Electroencephalography was recorded continuously. Brief-pulse stimulation technique was applied with right unilateral stimulation using the Thymatron System II apparatus (Somatics, Lake Bluff, IL, USA).

Individual seizure threshold, defined as stimulus dosage that elicited an EEG seizure of at least 15 s was titrated during the first treatment. EEG seizure duration and quality were measured by the psychiatrist by analysis of spike and wave activity. Stimulus duration was in a range from six to eight seconds with a pulse width from 0.5 to 1.0 ms and a frequency from 10 to 70 Hz. Maximum output was 504 mC current.

Statistics

Continuous interval scaled data were tested for normal distribution using the Shapiro-Wilk test. The influence of parameters and covariates on EEG seizure duration was analyzed using a generalized linear model for repeated measurements. The following parameters were included as nominal factors: sex, etomidate, S-ketamine, remifentanil, theophylline, thiopental, and session. Age and ECT energy were included as continuous covariates. Data are reported as mean ± SD and range. Statistical analysis was performed using IBM SPSS statistics 21.

Results

We analyzed 786 ECT sessions of 78 patients. The demographic data are summarized in Table 1. Each patient underwent on average 10 ± 6 (1–30 ECT sessions. Mean EEG seizure duration was 58 ± 24 (3–172) seconds. The energy level ranged from 25.2 to 504 mC.
Table 1

Patient data. Data are given as mean ± SD (range) or number

Male/female

39/39

Age (yrs.)

51 ± 13 (21–77)

Body weight (kg)

83 ± 16 (42–135)

Height (cm)

172 ± 9 (155–192)

BMI (kg/m2)

28.1 ± 4.7 (15.2–42.6)

Figure 1a shows how often each drug was used over all ECT sessions. The three most common used drugs (combinations) were: etomidate alone, etomidate with S-ketamine, theophylline, and remifentanil, and etomidate with remifentanil. Figure 1b shows how often a drug was administered alone or a combination of one or more different drugs was used in the ECT sessions. Etomidate was the most commonly used drug, followed by theophylline, remifentanil and S-ketamine. These three drugs were used in comparable numbers of ECT sessions (Fig. 1b), which is important for the statistical power of this study. Thiopental did not play a substantial role. In about half of the ECT sessions etomidate was given alone. In the other half etomidate was combined with one or more other drugs.
Fig. 1

Incidence of administered drug combinations (a) and cumulative use of drugs (b). Eto: etomidate, Sket: S-ketamine, Theo: theophylline, Remi: remifentanil, Thio: thiopental

Table 2 shows the results of the generalized linear model. Administration of theophylline was the only parameter with a significant effect on EEG seizure duration in our patient population. With theophylline, the estimated marginal mean (± standard error) of the EEG seizure duration was 64 ± 5 s, compared to 54 ± 5 s in sessions without theophylline (p < 0.001).
Table 2

Significance of the influence of the study parameters on EEG seizure duration, as obtained by analysis with a generalized linear model for repeated measurements

Parameter

Significance

Age

0.61

Sex

0.34

Etomidate

0.86

S-ketamine

0.58

Remifentanil

0.87

Theophylline

<0.001

Thiopental

0.98

Energy

0.076

Session

0.15

Discussion

This study showed that in our patient population only theophylline significantly prolonged seizure duration whereas other drugs that are commonly used for ECT like S-ketamine, remifentanil, thiopental had no significant effect on EEG seizure duration. One has to keep in mind that the other interventions might still have an effect on seizure duration but have failed to reach statistical significance secondary to insufficient number of cases or smaller effect size. We also demonstrated that demographic factors such as age or gender and external factors such as number of sessions or energy level had – at least in our patient population - no significant effect on EEG seizure duration.

Despite the fact that several investigations on the influence of drugs on seizure quality and duration have been performed and published, there is no generally accepted treatment protocol.

Methohexital used to be the gold standard for ECT secondary to its minimal anticonvulsant effects compared to other barbiturates, but has fallen out of favour since there was a lack of availability especially on the US market. The introduction and widespread clinical use of other hypnotic drugs, such as etomidate and propofol also contributed to the decreased use of barbiturates. Tan et al. [7] performed a study in which 20 patients received either propofol for their first, and etomidate for their second ECT session or vice versa. They found that etomidate was associated with a significantly longer motor and EEG seizure duration compared to propofol. Vaidya et al. demonstrated in a retrospective study that patients receiving propofol required significantly more treatments than those receiving methohexital when right unilateral electrode placement was used. Propofol was also associated with a significantly higher requirement for bilateral ECT and higher stimulus dosing. Seizure duration was significantly shorter in the propofol condition, with more patients requiring re-stimulation for brief seizures [11]. In another study Sackeim et al. showed that increasing the electrical dosage increases the efficacy in patients receiving right unilateral ECT [12], which is known to have less cognitive side effects compared to bilateral stimulation.

A previous study reported that S-ketamine lead to longer motor seizure duration than metohexital [6]. However, in a recently published blinded study with more than 80 patients, no significant effect on seizure duration was found when ketamine was added to sevoflurane anesthesia for ECT [13]. Hooten demonstrated that combining methohexital or propofol with short-acting opioids such as remifentanil prolonged seizure duration in patients with inadequate seizure quality [14]. These findings have been corroborated by a recently published study that found longer seizure duration in patients receiving (a reduced dose of) propofol plus remifentanil when compared to propofol alone [15]. Our results suggest that adding of remifentanil has no significant effect on EEG seizure duration when etomidate is used for induction of anesthesia.

Theophylline is a nonselective adenosine receptor antagonist. Adenosine is a powerful endogenous anticonvulsant that can terminate seizures, and extracellular adenosine is increased after seizures in patients with intractable epilepsy [16]. Thus, theophylline with its adenosine antagonistic effects has been known to lower seizure thresholds and should be used judiciously in patients with pre-existing seizure disorders. In patients undergoing ECT with a history of inadequate seizure quality or duration this potential adverse effect can be used to improve and prolong seizure quality and duration, respectively.

Devanand et al. [17] described a case of a 23-year-old man undergoing ECT after a suicide attempt despite a 4-week treatment with haloperidol. The patient was also taking theophylline (1200 mg per day) for chronic asthma. The patient showed an extremely prolonged seizure that eventually stopped after receiving multiple boluses of diazepam for a cumulative dose of 20 mg. Swartz and Lewis [18] published an interesting study in which they used oral theophylline (200-400 mg) given 10 h prior to ECT in order to increase seizure length in patients that previously had insufficient seizure durations. They reported a significant average increase of almost 14 s and no adverse effects from theophylline. Leentjens et al. [19] administered theophylline intravenously 30 min prior to seizure induction to patients that developed seizure inhibition during a course of ECT. A dose of 100-200 mg was found to effectively prolong seizure durations in all patients with the same or lower electrical doses that had failed to elicit adequate seizures before. Similarly, Stern et al. [3] reported an increase in duration for both EEG and clinical seizure in patients receiving aminophylline. In addition, they showed that this effect was maintained for three subsequent ECT sessions. In a very recent retrospective study by Kemp et al. [20] the effect of orally administered theophylline on seizure duration was investigated. They found a significant increase in seizure duration after administering oral theophylline. We have chosen to administer theophylline intravenously for several reasons: 1) It is logistically easier to administer the drug a few minutes prior to seizure induction than to time the intake of the pill on the general psychiatric floor, 2) patients have intravenous access and standard monitors established and could be treated immediately, in the unlikely scenario of an adverse event such as tachycardia – and 3) intravenous administration is better accepted by patients.

Intravenously or orally administered caffeine has also been used to increase seizure duration [21]. Since intravenous caffeine is not readily available in the country where this study was performed and we did not want to rely on orally administered drugs for increasing seizure duration for the above mentioned reasons, we do not use this drug in our clinical practice.

Other demographic or clinical parameter like age, session number, or energy level did not reach statistical significance for an effect on the EEG seizure duration in our study. This is in contrast to a large study published by Rasimas et al. [22] where significant effects of both age and session number were reported. In this study however, the vast majority of the 519 patients received bitemporal stimulation, whereas we only included patients receiving unilateral stimulation. Similar to our results, gender did not significantly affect seizure duration in this study.

Conclusion

In our study population only the effect of theophylline on EEG seizure duration in patient undergoing ECT reached statistical significance. Since prolonged seizure duration is supposed to be directly related with significant better outcome, theophylline may be effectively improving outcome in patients with short seizure duration. However, further investigations on correlation between drug management - especially use of theophylline - and patients’ outcome need to be performed.

Abbreviations

ECT: 

Electroconvulsive therapy

EEG: 

Electroencephalogram

US: 

United States

Declarations

Acknowledgements

We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding program Open Access Publishing.

Funding

The research was done by institutional resources only. There was no funding.

Availability of data and materials

The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AT - conceived the idea and designed the study, wrote the manuscript. MEW - participated in the design of the study and assisted in data analysis. JW – collected the ECT-data, revised the manuscript. WS – edited the manuscript and helped with study design. HI – was involved in data analysis and statistical support. HJS – edited the manuscript and collected the anesthesia data. TM – designed the study and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the ethics committee of the University Erlangen-Nuremberg by short correspondence from May 2012 without the need of informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. The authors have no conflicts of interest or financial disclosures to report.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, School of Medicine
(2)
Department of Anesthesiology, University Hospital of Erlangen
(3)
Department of Psychiatry and Psychotherapy, University Hospital Zürich
(4)
Department of Psychiatry, University Hospital of Erlangen

References

  1. Gazdag G, Bitter I, Ungvari GS, Baran B, Fink M. Laszlo Meduna's pilot studies with camphor inductions of seizures: the first 11 patients. J ECT. 2009;25(1):3–11.View ArticlePubMedGoogle Scholar
  2. Braun B, Kornhuber J. Adolf Abraham Gustav Bingel (1901–1982): Pionier der Elektrokonvulsionsbehandlung in Deutschland. Fortschr Neurol Psychiatr. 2013;81(10):589–91.Google Scholar
  3. Stern L, Dannon PN, Hirschmann S, Schriber S, Amytal D, Dolberg OT, Grunhaus L. Aminophylline increases seizure length during electroconvulsive therapy. J ECT. 1999;15(4):252–7.View ArticlePubMedGoogle Scholar
  4. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5–9.View ArticlePubMedGoogle Scholar
  5. Kornhuber J, Weller M. Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. Convuls Ther. 1995;11(2):104–9.PubMedGoogle Scholar
  6. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, Oliver WC, Abenstein JP. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014;215(2):362–5.View ArticlePubMedGoogle Scholar
  7. Tan HL, Lee CY. Comparison between the effects of propofol and etomidate on motor and electroencephalogram seizure duration during electroconvulsive therapy. Anaesth Intensive Care. 2009;37(5):807–14.PubMedGoogle Scholar
  8. Simpson KH, Halsall PJ, Carr CM, Stewart KG. Propofol reduces seizure duration in patients having anaesthesia for electroconvulsive therapy. Br J Anaesth. 1988;61(3):343–4.View ArticlePubMedGoogle Scholar
  9. Wang CC, Lin CH, Chiu YC, Tseng CC. The Clonic phase of seizures in patients treated with electroconvulsive therapy is related to age and stimulus intensity. Front Psychiatry. 2013;4:166.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Tzabazis A, Schmitt HJ, Ihmsen H, Schmidtlein M, Zimmermann R, Wielopolski J, Munster T. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT. 2013;29(3):189–95.View ArticlePubMedGoogle Scholar
  11. Vaidya PV, Anderson EL, Bobb A, Pulia K, Jayaram G, Reti I. A within-subject comparison of propofol and methohexital anesthesia for electroconvulsive therapy. J ECT. 2012;28(1):14–9.View ArticlePubMedGoogle Scholar
  12. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, McElhiney MC, Coleman EA, Settembrino JM. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328(12):839–46.View ArticlePubMedGoogle Scholar
  13. Erdil F, Ozgul U, Colak C, Cumurcu B, Durmus M. Effect of the addition of Ketamine to Sevoflurane anesthesia on seizure duration in electroconvulsive therapy. J ECT. 2015;31(3):182–5.View ArticlePubMedGoogle Scholar
  14. Hooten WM, Rasmussen KG Jr. Effects of general anesthetic agents in adults receiving electroconvulsive therapy: a systematic review. J ECT. 2008;24(3):208–23.View ArticlePubMedGoogle Scholar
  15. Kadoi Y, Saito S. Effects of adding remifentanil to propofol anesthesia on systemic hemodynamics, cardiac output, and middle cerebral artery flow velocity during electroconvulsive therapy: a pilot study. J ECT. 2015;31(2):98–100.View ArticlePubMedGoogle Scholar
  16. During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol. 1992;32(5):618–24.View ArticlePubMedGoogle Scholar
  17. Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in a patient receiving theophylline. J Clin Psychopharmacol. 1988;8(2):153.View ArticlePubMedGoogle Scholar
  18. Swartz CM, Lewis RK. Theophylline reversal of electroconvulsive therapy (ECT) seizure inhibition. Psychosomatics. 1991;32(1):47–51.View ArticlePubMedGoogle Scholar
  19. Leentjens AF, van den Broek WW, Kusuma A, Bruijn JA. Facilitation of ECT by intravenous administration of theophylline. Convuls Ther. 1996;12(4):232–7.PubMedGoogle Scholar
  20. Kemp MF, Allard J, Paquet M, Marcotte P. Impact of an oral theophylline loading dose pre-electroconvulsive therapy: a retrospective study in patients with missed or inadequate seizures. J ECT. 2015;31(1):37–42.View ArticlePubMedGoogle Scholar
  21. Rosenquist PB, McCall WV, Farah A, Reboussin DM. Effects of caffeine pretreatment on measures of seizure impact. Convuls Ther. 1994;10(2):181–5.PubMedGoogle Scholar
  22. Rasimas JJ, Stevens SR, Rasmussen KG. Seizure length in electroconvulsive therapy as a function of age, sex, and treatment number. J ECT. 2007;23(1):14–6.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement